Surface Oncology Inc (NASDAQ:SURF) insider Robert W. Ross sold 4,000 shares of the business’s stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $10.05, for a total transaction of $40,200.00. Following the completion of the transaction, the insider now owns 101,000 shares of the company’s stock, valued at approximately $1,015,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of SURF opened at $9.42 on Friday. Surface Oncology Inc has a 1-year low of $1.31 and a 1-year high of $10.25. The stock has a market cap of $375.92 million, a PE ratio of -10.70 and a beta of 2.49. The company has a debt-to-equity ratio of 0.46, a current ratio of 11.12 and a quick ratio of 11.12. The firm has a fifty day moving average price of $6.88 and a 200 day moving average price of $5.03.
Surface Oncology (NASDAQ:SURF) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.02. Surface Oncology had a negative net margin of 70.90% and a negative return on equity of 32.89%. As a group, equities analysts expect that Surface Oncology Inc will post -0.72 EPS for the current fiscal year.
SURF has been the subject of several research reports. Wedbush initiated coverage on shares of Surface Oncology in a research note on Thursday, August 27th. They issued an “outperform” rating and a $12.00 price target for the company. Zacks Investment Research raised shares of Surface Oncology from a “sell” rating to a “hold” rating and set a $6.50 price objective for the company in a research report on Thursday, August 13th. HC Wainwright started coverage on shares of Surface Oncology in a research report on Friday, September 4th. They set a “buy” rating and a $11.00 price objective for the company. BidaskClub raised shares of Surface Oncology from a “sell” rating to a “hold” rating in a research report on Thursday, September 10th. Finally, ValuEngine cut shares of Surface Oncology from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Surface Oncology has a consensus rating of “Hold” and an average target price of $9.63.
Surface Oncology Company Profile
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27.
Featured Article: What Is Dividend Yield and How Do You Calculate It?
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.